Is HIMS a buy

Hims & Hers Health (HIMS) is a buy. Here's why:

1. Strong Financial Growth: Hims & Hers Health has reported a net income of $13.3 million and total revenue of $315.65 million as of June 30, 2024. The company's net income has grown by 285.79% year-over-year, and its revenue has increased by 51.82%.

2. Attractive Valuation: The company's Price to Book Ratio is 10.28, P/S Ratio is 3.13, and P/E Ratio is -1581.7. The high P/E ratio could be due to the company's high growth rate, and the other valuation metrics suggest a reasonable value for the stock.

3. Positive Technical Indicators: The stock is currently trading above its 5-Day, 10-Day, and 20-Day moving averages, which could indicate a bullish trend. This is a favorable sign for buyers.

4. Strong Buy Consensus: The consensus rating for HIMS is "Strong Buy" with an average price target of $21.57, which suggests that analysts are optimistic about the stock's future performance.

5. Positive Fund Flow: The net fund flow for HIMS is positive, with a net fund flow of $7.47 million, which could indicate that there is buying pressure in the stock. The net fund flow (block order) is also positive, with a net fund flow of $4.8 million, which suggests that large investors are also buying the stock.

In conclusion, Hims & Hers Health's strong financial growth, attractive valuation, positive technical indicators, strong buy consensus, and positive fund flow suggest that the stock is a buy. Investors should consider these factors when making a decision to buy the stock.